Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SZSE:002932) commences share repurchases on March 27, 2024, under the program mandated by shareholders in the Extraordinary General Meeting held on March 18, 2024. As per the mandate, the company is authorized to repurchase up to CNY 350 million worth of its shares. The shares will be repurchased at no more than 23 per share.

The purpose of the program is to use the repurchased for employee stock ownership plans or equity incentives, to safeguard company value and shareholder rights. If the company fails to use the repurchased shares for the said purpose within 3 years of completion of the program, the unused shares will be cancelled. The program will be funded from company's own funds.

The authorization will be valid for a period of 12 months.